Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Pegylated interferon-alpha-2a
Introduction
Overview
Overview
Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action – both antiviral and on the immune system.
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, ‘normal’ levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
External links
External links
- PMPRB at pmprb-cepmb.gc.ca
- Pegasys at the US National Library of Medicine Medical Subject Headings (MeSH)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]